Anti-PD-1, anti-PD-L1 interaction and anti-CTLA4 treatment restored the functions of CD8+ and CD4+ T cells, thereby enhancing the efficacy of immunotherapy in patients with HCC 37. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.